Save after changing Favorites. Use Share Link when you want the same list on another device.
Your link (Favorites):
All Favorites
#
Name
Description
Category
Type
Source
Website
TEN
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Denosumab, ATC M05BX04 für die Zeit 01.07.2026 - 30.06.2028 (zzgl. Verlängerungsoption 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Betamethason und Salicylsäure (ausschl. Dafo. LOE), f. d. Z. 01.07.26 - 30.06.28 (zzgl. V.-Option 1x12 Mon)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Pilocarpin, ATC N07AX01 für die Zeit 01.07.2026 - 30.06.2028 (zzgl. Verlängerungsoption 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Testosteron (ausschl. Testosteron als Enantat-Salz), f. d. Z. 01.07.26 - 30.06.28 (zzgl. V.-Option 1x12 Mon)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Midazolam, ATC N03AE02 für die Zeit 01.07.2026 - 30.06.2028 (zzgl. Verlängerungsoption 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Calcipotriol + Betamethason (ausschl. Dafo. CRE), für die Zeit 01.07.26 - 30.06.28 (zzgl. V.-Option 1x12 M.)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Tolvaptan (ausschl. Wirkstärke 7,5mg in der Normgröße N2), f. d.Z. 01.7.26 - 30.6.28 (zzgl. V.-Option 1x12 M)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Promethazin (ausschl. Dafo. TEI), ATC N05CM22 für die Zeit 01.07.26 - 30.06.28 (zzgl. V.-Option 1x12 Mon)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Spironolacton (ausschl. Wirkstärke 25mg), ATC C03DA01 f. d. Z. 01.07.26 - 30.06.28 (zzgl. V.-Option 1x12 Mon)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Octreotid (ausgeschlossen Dafo. DFL,PLS,TRS), ATC H01CB02 f. d. Z. 1.7.26-30.6.28 (zzgl. V.-Option 1x12 Mon)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Risperidon (ausschl. Dafo. PLD), ATC N05AX08 für die Zeit 01.07.26 - 30.06.28 (zzgl. V.-Option 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Calciumcarbonat + Colecalciferol, ATC M05BB04 für die Zeit 01.07.26 - 30.06.28 (zzgl. V.-Option 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Dabigatran (ausschl. in der Normgröße N3), ATC B01AE07 f. d. Z. 01.7.26 - 30.6.28 (zzgl. V.-Option 1x12 Mon)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Formoterol (ausschl. Dafo. DOS), ATC R03AC13 für die Zeit 01.07.26 - 30.06.28 (zzgl. V.-Option 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Granisetron (ausschl. Dafo. PFT), ATC A04AA02 für die Zeit 01.07.26 - 30.06.28 (zzgl. V.-Option 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Ivermectin (ausschl. Dafo. CRE), ATC D11AX22 für die Zeit 01.07.26 - 30.06.28 (zzgl. V.-Option 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Vigabatrin (ausschl. Dafo. FTA), ATC N03AG04 für die Zeit 01.07.26 - 30.06.28 (zzgl. V.-Option 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Darifenacin, ATC G04BD10 für die Zeit 01.07.2026 - 30.06.2028 (zzgl. Verlängerungsoption 1x12 Monate)
Spain – Safety training services – Homologación de proveedores para el servicio de formación para el personal del Ens d'Abastament Ter-Llobregat en materias recurrentes y necesidades formativas específicas mediante un Sistema Dinámico de Adquisición
Czechia – Chemical products – UTB - Dynamický nákupní systém na chemikálie II
ted.europa.eu
Buyer: Univerzita Tomáše Bati ve Zlíně | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2029-05-06
TenderProcurement ContractCzechiaOpen
AmountNot provided on the source page. Please check the official source.
DeadlineMay 6, 2029
Buyer: Univerzita Tomáše Bati ve Zlíně | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2029-05-06
TEN
Czechia – Chemical products – UTB - Dynamický nákupní systém na chemikálie II
ted.europa.eu
Buyer: Univerzita Tomáše Bati ve Zlíně | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2029-05-06
TenderProcurement ContractCzechiaOpen
AmountNot provided on the source page. Please check the official source.
DeadlineMay 6, 2029
Buyer: Univerzita Tomáše Bati ve Zlíně | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2029-05-06
TEN
Lithuania – Engineering works and construction works – SUSISIEKIMO KOMUNIKACIJŲ IR KITŲ INŽINERINIŲ STATINIŲ STATYBOS DARBAI, Nr. 1924
ted.europa.eu
Buyer: Uždaroji akcinė bendrovė "GRINDA" | Notice type: cn-standard | Procedure: restricted | Contract: works | Deadline: 2029-05-06
TenderProcurement ContractLithuaniaOpen
AmountNot provided on the source page. Please check the official source.
DeadlineMay 6, 2029
Buyer: Uždaroji akcinė bendrovė "GRINDA" | Notice type: cn-standard | Procedure: restricted | Contract: works | Deadline: 2029-05-06
GRA
NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional)
grants.gov
The National Institutes of Health (NIH) seeks to advance its mission by maintaining strong, productive, and secure international research collaboratio...
GrantCash GrantUnited StatesOpen
AmountNot provided on the source page. Please check the official source.
DeadlineMay 7, 2029
The National Institutes of Health (NIH) seeks to advance its mission by maintaining strong, productive, and secure international research collaborations in support of the NIH mission. The NIH Collaborative International Research Project (Parent Announcement) supports international research collaborations. This opportunity specifically implements an award structure of prime domestic awards with independent foreign awards that are linked to the prime. This structure provides NIH with oversight capacity for international collaborations, and allows NIH to track international funding, as identified in NOT-OD-25-104. This funding opportunity is specifically designed for NIH to support funded international collaborations between a domestic prime organization and foreign organizations. This NOFO should not be used for foreign consultants, purchasing unique equipment or supplies from foreign vendors, foreign collaborations that do not involve NIH funding or any other foreign component that woul...
GRA
Biological Testing Facility for Contraception & Reproductive Health (X01 Clinical Trial Not Allowed)
grants.gov
The purpose of this notice of funding opportunity (NOFO) is to provide investigators with a mechanism to request services from the state-of-the-art Bi...
GrantCash GrantUnited StatesOpen
AmountNot provided on the source page. Please check the official source.
DeadlineMay 7, 2029
The purpose of this notice of funding opportunity (NOFO) is to provide investigators with a mechanism to request services from the state-of-the-art Biological Testing Facility that would advance their contraceptive development or reproductive health programs. This NOFO aims to position innovative and validated methods for future regulatory submission and/or clinical development. Applicants do not need to have current NIH funding to apply, but priority may be given to programs receiving NIH support at the time of application submission.
No saved opportunities on this page
Use the star icon near an opportunity title to add it to Favorites.
📅 Best viewed on desktop - or rotate your phone to landscape mode.
#
Opportunity
Type
Region / Country
Amount
Deadline
Source
43976
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Denosumab, ATC M05BX04 für die Zeit 01.07.2026 - 30.06.2028 (zzgl. Verlängerungsoption 1x12 Monate)Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2029-05-05
Tender
Procurement Contract
Germany
Not provided on the source page. Please check the official source.
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Dabigatran (ausschl. in der Normgröße N3), ATC B01AE07 f. d. Z. 01.7.26 - 30.6.28 (zzgl. V.-Option 1x12 Mon)Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2029-05-05
Tender
Procurement Contract
Germany
Not provided on the source page. Please check the official source.
Spain – Safety training services – Homologación de proveedores para el servicio de formación para el personal del Ens d'Abastament Ter-Llobregat en materias recurrentes y necesidades formativas específicas mediante un Sistema Dinámico de AdquisiciónBuyer: Ens d'Abastament d'Aigua Ter-Llobregat (ATL) | Notice type: cn-standard | Procedure: restricted | Contract: services | Dead...
Tender
Procurement Contract
Spain
Not provided on the source page. Please check the official source.
Buyer: Univerzita Tomáše Bati ve Zlíně | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2029-05-06
43998
Lithuania – Engineering works and construction works – SUSISIEKIMO KOMUNIKACIJŲ IR KITŲ INŽINERINIŲ STATINIŲ STATYBOS DARBAI, Nr. 1924Buyer: Uždaroji akcinė bendrovė "GRINDA" | Notice type: cn-standard | Procedure: restricted | Contract: works | Deadline: 2029-05-...
Tender
Procurement Contract
Lithuania
Not provided on the source page. Please check the official source.
Buyer: Uždaroji akcinė bendrovė "GRINDA" | Notice type: cn-standard | Procedure: restricted | Contract: works | Deadline: 2029-05-06
43999
NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional)The National Institutes of Health (NIH) seeks to advance its mission by maintaining strong, productive, and secure international r...
Grant
Cash Grant
United States
Not provided on the source page. Please check the official source.
The National Institutes of Health (NIH) seeks to advance its mission by maintaining strong, productive, and secure international research collaborations in support of the NIH mission. The NIH Collaborative International Research Project (Parent Announcement) supports international research collaborations. This opportunity specifically implements an award structure of prime domestic awards with independent foreign awards that are linked to the prime. This structure provides NIH with oversight capacity for international collaborations, and allows NIH to track international funding, as identified in NOT-OD-25-104. This funding opportunity is specifically designed for NIH to support funded international collaborations between a domestic prime organization and foreign organizations. This NOFO should not be used for foreign consultants, purchasing unique equipment or supplies from foreign vendors, foreign collaborations that do not involve NIH funding or any other foreign component that would not result in a foreign subaward. All collaborative international research project applications must include at least 1 international subproject. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes, Centers and Offices (ICOs) based on their scientific missions. The application will be evaluated as a whole, and the international subproject(s) will be evaluated on whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditi...
44000
Biological Testing Facility for Contraception & Reproductive Health (X01 Clinical Trial Not Allowed)The purpose of this notice of funding opportunity (NOFO) is to provide investigators with a mechanism to request services from the...
Grant
Cash Grant
United States
Not provided on the source page. Please check the official source.
The purpose of this notice of funding opportunity (NOFO) is to provide investigators with a mechanism to request services from the state-of-the-art Biological Testing Facility that would advance their contraceptive development or reproductive health programs. This NOFO aims to position innovative and validated methods for future regulatory submission and/or clinical development. Applicants do not need to have current NIH funding to apply, but priority may be given to programs receiving NIH support at the time of application submission.
No saved opportunities on this page. Use the star icon near an opportunity title.
